Osteoporosis / Bone Density Loss (PPI-Induced) Secondary to Service-Connected Condition (Treated with Long-Term Proton Pump Inhibitors)

Yes. Under 38 CFR § 3.310(a), any disability proximately caused or chronically worsened by a service-connected condition is itself service-connected. Osteoporosis / Bone Density Loss (PPI-Induced) is a documented secondary pairing for Service-Connected Condition (Treated with Long-Term Proton Pump Inhibitors) with strong medical evidence. A nexus letter from a qualified physician linking the two conditions is the most reliable way to establish this connection.

The gold standard is a private nexus opinion stating — to at least a 50% probability ("at least as likely as not") — that the secondary condition was caused or aggravated by the primary service-connected condition. Peer-reviewed medical literature supporting the physiological mechanism strengthens the nexus. Treatment records documenting the onset or worsening of the secondary condition in temporal relation to the primary are supporting evidence.

The VA rates Osteoporosis / Bone Density Loss (PPI-Induced) separately under its own 38 CFR Part 4 diagnostic code, then combines it with Service-Connected Condition (Treated with Long-Term Proton Pump Inhibitors) and all other service-connected ratings using the combined ratings formula under § 4.25. The formula applies the whole-person concept: a 50% combined existing rating plus a new 30% rating yields 65% (rounded to 70%), not 80%.

38 CFR § 3.310(a) states: "Disability which is proximately due to or the result of a service-connected disease or injury shall be service connected." The aggravation variant under § 3.310(b) applies where the primary condition permanently worsens a pre-existing disability beyond its natural progression. Both standards require a showing of nexus — a medical or scientific link between the primary condition and the secondary.

The medical evidence supporting Osteoporosis / Bone Density Loss (PPI-Induced) as secondary to Service-Connected Condition (Treated with Long-Term Proton Pump Inhibitors) is rated strong. Long-term proton pump inhibitor (PPI) use for service-connected GERD produces osteoporosis through impaired calcium absorption. PPIs raise gastric pH above the threshold needed for calcium carbonate dissolution (pH < 3), reducing dietary calcium bioavailability by 40-60%. Additionally, PPIs may directly inhibit osteoclast proton pumps (H+/K+ ATPase) in bone, altering normal bone remodeling. Chronic hypochlorhydria from PPIs also impairs magnesium and vitamin B12 absorption, both of which are cofactors in bone metabolism. FDA black box warning (2010, updated 2011) recognizes PPI-associated fracture risk: hip fracture risk increases 25-44% with PPI use >1 year. Veterans with GERD secondary to medications or military stress often take PPIs for decades.

The VA will not solicit nexus evidence on your behalf for secondary claims. In practice, a written nexus opinion from a private physician or independent medical examiner is essential — the VA's Compensation & Pension (C&P) examiner is not required to produce a favorable nexus opinion, and the VA has discretion to weigh competing opinions. Submitting a private nexus letter at the time of filing is the most reliable strategy.